AI Article Synopsis
- Recent research has highlighted the potential of circulating microRNAs (miRNAs) as biomarkers in breast cancer, particularly miR-451 for inflammatory breast cancer (IBC) and miR-337-5p and miR-30b for non-inflammatory breast cancer (non-IBC).
- The study compared the serum levels of 12 different miRNAs among 20 patients each of IBC, non-IBC, and healthy controls using TaqMan qPCR and found significant correlation differences in miRNA expression related to cancer state and characteristics like menopausal status and HER2 status.
- Results indicated that specific miRNAs, such as miR-335 and miR-24, were overexpressed in specific patient groups, suggesting their potential role as
Article Abstract
Recent discovery showing the presence of microRNAs (miRNAs) in the circulation sparked interest in their use as potential biomarkers. Our previous studies showed the diagnostic potential of miR-451 as a serological marker for inflammatory breast cancer (IBC), miR-337- 5p and miR-30b for non-inflammatory breast cancer (non-IBC). The aim of this study is to investigate the prognostic values of circulating miRNAs by comparing the amounts of 12 circulating miRNAs in the serum of IBC and non-IBC from Tunisian breast cancer patients, and by determinating whether correlated pairs of miRNAs could provide useful information in the diagnosis of IBC and non-IBC patients. TaqMan qPCR was performed to detect circulating expression of miRNAs in serum of 20 IBC, 20 non-IBC and 20 healthy controls. Nonparametric rank Spearman rho correlation coefficient was used to examine the prognostic value of miRNAs and to assess the correlation profile between miRNAs expression. Further, a large number of miRNAs were highly correlated (rho>0.5) in both patients groups and controls. Also, the correlations profiles were different between IBC, non-IBC and healthy controls indicating important changes in molecular pathways in cancer cells. Our results showed that miR-335 was significantly overexpressed in premenopausal non-IBC patients; miR-24 was significantly overexpressed in non-IBC postmenopausal patients. Patients with previous parity had higher serum of miR-342-5p levels than those without. Furthermore, patients with HER2+ IBC present lower serum levels of miR-15a than patients with HER2- disease. Together, these results underline the potential of miRNAs to function as diagnostic and prognostic markers for IBC and non-IBC, with links to the menopausal state, Her2 status and parity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7314/apjcp.2016.17.4.1801 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers.
ESMO Open
January 2025
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, USA; Harvard Medical School, Boston, USA.
Background: The HER2DX assay predicts long-term prognosis and pathologic complete response (pCR) in patients with early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer receiving neoadjuvant systemic therapy but has not been evaluated in inflammatory breast cancer (IBC).
Patients And Methods: HER2DX was analyzed in baseline biopsy tissues from 23 patients with stage III HER2-positive IBC on a phase II trial (NCT01796197) treated with neoadjuvant trastuzumab, pertuzumab, and paclitaxel (THP). To assess the assay's predictive accuracy for pCR in IBC, clinical-pathological features and outcomes from this IBC cohort were compared with 156 patients with stage III HER2-positive non-IBC from four different cohorts.
Characterization of mammographic markers of inflammatory breast cancer (IBC).
Phys Med
January 2025
Department of Radiology, University of Michigan, Ann Arbor, MI 48109, USA.
Purpose: Inflammatory breast cancer (IBC) is a rare and aggressive type of breast cancer, as many physicians may not be aware of it in terms of symptoms and diagnosis. Mammography is the first choice in breast screenings and diagnosis. Because of a lack of expertise and imaging datasets, IBC portrayal and machine learning-based diagnosis systems have not yet been studied thoroughly.
View Article and Find Full Text PDFGenomic and transcriptomic analyses identify distinctive features of triple-negative inflammatory breast cancer.
NPJ Precis Oncol
November 2024
Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Article Synopsis
- Triple-negative inflammatory breast cancer (TN-IBC) is the most aggressive form of breast cancer, and its specific genetic and immune characteristics are not well understood.
- This study conducted extensive genomic analyses of TN-IBC tumors from a phase II clinical trial, comparing them to stage III triple-negative non-inflammatory breast cancer (TN-non-IBC) samples.
- Key findings revealed that TN-IBC tumors have unique features, such as a lower mutation load and the presence of immune components that may hinder chemotherapy response, indicating a need for further research to identify potential biomarkers and treatment targets.
Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study.
Eur J Cancer
December 2024
Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. Electronic address:
Article Synopsis
- * A study involving 42 patients from various international centers aimed to measure the effectiveness of combining ICIs with chemotherapy, with expectations of improved 6-month progression-free survival (rwPFS) rates.
- * Results revealed a disappointing 6-month rwPFS rate of 30% and a median overall survival of 15.7 months for patients, prompting a call for further research on the efficacy of immunotherapy in mTN-IBC, contrary to earlier expectations regarding its immune-vulnerability.
Multifunctional role of the tumor-associated monocytes/macrophages in the metastatic potential of inflammatory breast cancer.
QJM
December 2024
Department of Microbiology, NYU Grossman School of Medicine, New York, NY, USA.
Article Synopsis
- Inflammatory breast cancer (IBC) is the most aggressive type of breast cancer, primarily affecting young women, especially in North Africa, and is characterized by rapid metastasis and unique biological properties.
- IBC typically presents with features such as positive metastatic lymph nodes, infiltration of specific immune cells (monocytes/macrophages), and the ability to progress quickly to distant metastasis.
- The review highlights the critical role of tumor-associated monocytes/macrophages (TAM/M) in IBC, focusing on how their interactions with IBC cells promote cancer progression, stem cell properties, drug resistance, and overall malignancy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!